Deschloroketamine: Difference between revisions

Line 2:

'''Deschloroketamine''' (also known as '''2'-Oxo-PCM''', '''O-PCM''', '''DXE''', and '''DCK''') is a novel ~~synthetic~~ [[psychoactive class::dissociative]] substance of the [[chemical class::arylcyclohexylamine]] ~~chemical~~ class ~~which~~ produces [[dissociative]], [[pain relief|anesthetic]] and [[hallucinogenic]] effects when [[Routes of administration|administered]].<ref name="name">Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20138515</ref><ref name="patent">Patent US 3254124 - Aminoketones and methods for their production | http://www.google.com/patents/US3254124</ref>

'''Deschloroketamine''' (also known as '''2'-Oxo-PCM''', '''O-PCM''', '''DXE''', and '''DCK''') is a lesser-known novel [[psychoactive class::dissociative]] substance of the [[chemical class::arylcyclohexylamine]] class that produces [[dissociative]], [[pain relief|anesthetic]] and [[hallucinogenic]] effects when [[Routes of administration|administered]].<ref name="name">Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20138515</ref><ref name="patent">Patent US 3254124 - Aminoketones and methods for their production | http://www.google.com/patents/US3254124</ref>

Early discussion over DCK has revolved around speculation over claims of antibacterial or immunosuppressant properties. If this speculation is valid, it is possible that its prolonged use could potentially pose a serious threat to one's health and immune system, which is why misuse of this substance is highly discouraged and caution to avoid treating it like its parent compound, [[ketamine]], is advised.<ref name="DCKAntibacterial">Preiss, D., & Tartar, A. (1998). U.S. Patent No. US5811464. Washington, DC: U.S. Patent and Trademark Office. | https://www.google.com/patents/US5811464</ref>

@@ Line 2: / Line 2: @@
 {{SubstanceBox/Deschloroketamine}}
-'''Deschloroketamine''' (also known as '''2'-Oxo-PCM''', '''O-PCM''', '''DXE''', and '''DCK''') is a novel synthetic [[psychoactive class::dissociative]] substance of the [[chemical class::arylcyclohexylamine]] chemical class which produces [[dissociative]], [[pain relief|anesthetic]] and [[hallucinogenic]] effects when [[Routes of administration|administered]].<ref name="name">Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20138515</ref><ref name="patent">Patent US 3254124 - Aminoketones and methods for their production | http://www.google.com/patents/US3254124</ref>
+'''Deschloroketamine''' (also known as '''2'-Oxo-PCM''', '''O-PCM''', '''DXE''', and '''DCK''') is a lesser-known novel [[psychoactive class::dissociative]] substance of the [[chemical class::arylcyclohexylamine]] class that produces [[dissociative]], [[pain relief|anesthetic]] and [[hallucinogenic]] effects when [[Routes of administration|administered]].<ref name="name">Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20138515</ref><ref name="patent">Patent US 3254124 - Aminoketones and methods for their production | http://www.google.com/patents/US3254124</ref>
 Early discussion over DCK has revolved around speculation over claims of antibacterial or immunosuppressant properties. If this speculation is valid, it is possible that its prolonged use could potentially pose a serious threat to one's health and immune system, which is why misuse of this substance is highly discouraged and caution to avoid treating it like its parent compound, [[ketamine]], is advised.<ref name="DCKAntibacterial">Preiss, D., & Tartar, A. (1998). U.S. Patent No. US5811464. Washington, DC: U.S. Patent and Trademark Office. | https://www.google.com/patents/US5811464</ref>